Ken Griffin Avrobio, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024
SELL
$1.15 - $1.48 $4,600 - $5,920
-4,000 Reduced 30.77%
9,000 $11,000
Q4 2023

Feb 14, 2024
BUY
$1.22 - $1.62 $5,124 - $6,804
4,200 Added 47.73%
13,000 $17,000
Q3 2023

Nov 14, 2023
BUY
$0.98 - $1.62 $1,470 - $2,430
1,500 Added 20.55%
8,800 $13,000
Q1 2023

May 15, 2023
BUY
$0.76 - $1.82 $304 - $728
400 Added 5.8%
7,300 $7,000
Q4 2022

Feb 14, 2023
BUY
$0.64 - $0.91 $4,416 - $6,279
6,900 New
6,900 $4,000

Others Institutions Holding AVRO

# of Institutions
1
Shares Held
559K
Call Options Held
0
Put Options Held
0
View Full List

About AVROBIO, Inc.

AVRO Quotes by TradingView
  • Ticker AVRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,773,900
  • Description
  • AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...
More about AVRO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email